In short
Clinical trials are investigating Ab-729 in people with chronic HBV infection. The study data focus on safety, tolerability, and treatment-related reactions in NA-suppressed subjects. These trials help show how Ab-729 is being tested in a Phase 2 setting.
Key points
- Clinical trials of Ab-729 are studying people with chronic HBV infection. The main trial listed is a Phase 2, interventional study in NA-suppressed subjects. It tests Ab-729, also called imdusiran, together with intermittent durvalumab dosing. The main focus is safety and tolerability, not just whether the treatment works. Researchers are measuring treatment-emergent adverse events, immune-related adverse events, lab changes, vital signs, physical exam findings, and ECG results. The trial was completed and enrolled 30 people.
Clinical trials overview
The available trial data show one interventional study of Ab-729 in people with chronic HBV infection. The study was titled an open-label study of imdusiran (AB-729) with intermittent dosing of durvalumab in subjects with chronic HBV infection.
Ab-729 is described in the trial record as imdusiran (AB-729), and the study also used durvalumab, listed as IMFINZI, as part of the treatment plan. The brief summary says the trial aimed to evaluate the safety and tolerability of imdusiran and durvalumab in NA-suppressed chronic HBV subjects.
Who was studied
The target population was people with chronic HBV infection, meaning long-lasting hepatitis B infection. The study specifically included NA-suppressed subjects, which means their hepatitis B virus was already being controlled with nucleic acid analog treatment.
This focus matters because the trial was not designed for all people with hepatitis B, but for a more specific group whose virus was already suppressed.
What the study tested
The trial tested Ab-729 together with intermittent dosing of durvalumab. Intermittent dosing means the medicine is given at set times rather than continuously.
The study used an open-label design, which means both the researchers and the participants knew what treatment was being given. This type of design is often used when the main goal is to watch safety and tolerability closely.
Study endpoints and safety checks
The primary outcome measures focused on safety. These included the frequency and severity of treatment-emergent adverse events (TEAEs), immune-related adverse events (irAEs), and treatment stops because of these events.
The study also measured laboratory abnormalities by cohort, which means researchers checked whether blood or other lab tests moved outside the normal range in each study group. In addition, the trial tracked vital signs, physical exam findings, and electrocardiogram (ECG) abnormalities to watch for possible safety concerns.
Trial status and size
The study was a Phase 2 trial, which is a mid-stage study that usually looks more closely at safety and early treatment effects. The trial status was completed, and the enrollment was 30 participants.
Because only one trial is listed in the source data, the current clinical picture for Ab-729 here is limited to this completed Phase 2 study in chronic HBV infection.